GT Biopharma Reports Full Year 2025 Financial Results

Stock Information for Coherus Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Coherus Oncology Inc.

GT Biopharma to Participate in the 38th Annual Roth Conference
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
THE SCARCITY DOCTRINE: 5 Assets Securing the 2026 Material Cycle
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.